



## ***Developmental Projects 2011*** **Request for Applications**

**Release Date:** Tuesday, November 1, 2011

**Application Receipt Date:** Wednesday, February 1, 2012 (any time that day)

**Peer Review:** February-March, 2012

**Anticipated Start Date:** May 1, 2012

The Rocky Mountain Regional Center of Excellence for Biodefense and Emerging Infectious Diseases Research (RMRCE) invites applications for competitive **one- or two-year *Developmental Project Awards***. The objective of these awards is to support innovative, cutting-edge research in areas that may yield discoveries leading to or facilitating the development of anti-bacterial or anti-viral products directed against **NIAID Category A, B, and C Priority Pathogens and emerging infectious disease (EID) agents\***. These are focused projects with a budget of \$125,000 to \$150,000 (Direct Costs) per year. We anticipate funding one (1) Developmental Project in the next funding cycle (May 1, 2012 to April 30, 2013). Second-year funding, if requested, will be dependent on the outcome of a rigorous mid-point review.

### ***Strategic Plan for the RMRCE***

All proposals must address how the application will support the RMRCE's strategic plan. The RMRCE is one of the regional consortia that comprise a national network of institutes and private corporations involved in biodefense-related research. The research network is focused on countering threats from bioterror agents and emerging infectious diseases. The primary objective of the RMRCE program is to support multifaceted basic and applied research activities that promote development of bacterial or viral therapeutics and therapeutic strategies targeting Category A, B, and C priority pathogens and EID agents.

***Proposals must complement existing strengths of the RMRCE research program. Pathogens currently being studied include:***

- *Burkholderia pseudomallei, Burkholderia mallei, Francisella tularensis and Mycobacterium tuberculosis*, under Integrated Research Focus 1: Bacterial Therapeutics.
- Flaviviruses, Alphaviruses, Bunyaviruses and Arenaviruses, under Integrated Research Focus 2: Viral Therapeutics.

Although any meritorious proposal complementing existing RMRCE strengths and focused toward the strategic plan will be considered, all applications must propose basic or applied research activities that promote development of improved bacterial or viral

therapeutics, including broad platform immunotherapeutic strategies. This may include diagnostics that specifically impact therapeutic decisions or monitor treatment outcome for pathogens under Integrated Research Focus 1 or 2. However, proposals whose aims are to develop any other type of diagnostics, or adjuvants and vaccines for disease prevention, will not be considered at this time.

A full application is due by Wednesday, February 1, 2012. Application materials and instructions for preparing the 5-page Research Plan are posted on the RMRCE web page ([www.rmrce.colostate.edu](http://www.rmrce.colostate.edu)).

Please direct questions to Kristine Bennett, (RMRCE Program Manager)  
[kristine.bennett@colostate.edu](mailto:kristine.bennett@colostate.edu).

\*<http://www.niaid.nih.gov/topics/BiodefenseRelated/Biodefense/research/Pages/CatA.aspx>